Table 2.
Effect of memantine on discontinuation, efficacy and safety outcomes in patients with Alzheimer’s disease
| Na | OR | 95%CI | I2 (%) | |
|---|---|---|---|---|
| All-cause discontinuation | 18 | 0.97 | 0.82, 1.14 | 14.9 |
| Discontinuation due to AE | 14 | 1.18 | 0.91, 1.53 | 34.4 |
| Discontinuation due to LoE | 7 | 0.40 | 0.18, 0.87 | 0 |
| N | SMD | 95%CI | I2 (%) | |
| Cognitive function | 17 | 0.15 | 0.08, 0.22 | 24.3 |
| Global change | 10 | 0.16 | 0.08, 0.24 | 29.3 |
| Neuropsychiatric symptoms | 15 | 0.16 | 0.09, 0.24 | 27.2 |
| Functional ability | 10 | 0.07 | −0.02, 0.15 | 14.7 |
| N | OR | 95%CI | I2 (%) | |
| Proportion patients AE | 6 | 1.05 | 0.88, 1.25 | 0 |
| Proportion patients SAE | 10 | 0.89 | 0.70, 1.13 | 18.3 |
| Mortality | 13 | 1.03 | 0.74, 1.44 | 0 |
AE adverse event, ChEI cholinesterase inhibitor, CI confidence interval, I2 heterogeneity, LoE lack of efficacy, N number of memantine-placebo comparisons, OR odds ratio, SAE severe adverse event
aOne study included had a factorial design